Autres langues Celcuity Inc.

Actions

CELC

US15102K1007

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
72,10 ^USD	-4,03%		-9,33%	-27,71%

02/10	Celcuity Inc. annonce la nomination de David W. Gryska au conseil d’administration ainsi qu’au comité d’audit et au comité des rémunérations, avec effet au 1er octobre 2026	CI
30/09	Celcuity Inc. annonce la disponibilité commerciale de REVTORPYK (gedatolisib) aux États-Unis	CI

Autres langues

02/10	Celcuity Inc. Announces Appointment of David W. Gryska to Board of Directors and Member of the Audit Committee and Compensation Committee, Effective October 1, 2026
02/10	Celcuity Appoints David Gryska To Its Board Of Directors
30/09	Celcuity Inc. Announces REVTORPYK? (Gedatolisib) Is Commercially Available In The United States
30/09	Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
01/09	Celcuity To Participate in Upcoming Investor Conferences
26/08	Celcuity Inc Submits Supplemental New Drug Application to Fda for Revtorpyk (Gedatolisib) for Hr+/Her2-, Pik3ca Mutant Locally Advanced or Metastatic Breast Cancer
26/08	Celcuity Submits Supplemental NDA for REVTORPYK in PIK3CA-Mutant Breast Cancer
26/08	Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
13/08	Celcuity Q2 Adjusted Loss Widens
13/08	Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12
13/08	Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
13/08	Celcuity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
30/07	Celcuity Announces FDA Approval And NCCN Guidelines Inclusion For REVTORPYK In Combination With Fulvestrant With Or Without Palbociclib
30/07	Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
15/07	Celcuity shares fall as launch delay eclipses US approval for breast cancer drug
15/07	Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
14/07	Celcuity Gets FDA Approval for Breast Cancer Drug
14/07	Celcuity's REVTORPYK Gets FDA Approval for HR+/HER2- Breast Cancer
14/07	Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
14/07	Celcuity Announces FDA Approval of REVTORPYK? (Gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
14/07	Correction to Celcuity Gets FDA Approval Headline
14/07	US FDA approves Celcuity's breast cancer drug
29/06	Celcuity Inc.(NasdaqCM:CELC) dropped from Russell 2000 Value Benchmark
29/06	Celcuity Inc.(NasdaqCM:CELC) dropped from Russell Microcap Value Benchmark Index